Chronic thromboembolic pulmonary hypertension anno 2021

Purpose of review In the past decades, the diagnostic and therapeutic management of chronic thromboembolic pulmonary hypertension (CTEPH) has been revolutionized. Recent findings Advances in epidemiological knowledge and follow-up studies of pulmonary embolism patients have provided more insight in the incidence and prevalence. Improved diagnostic imaging techniques allow accurate assessment of the location and extend of the thromboembolic burden in the pulmonary artery tree, which is important for the determination of the optimal treatment strategy. Next to the pulmonary endarterectomy, the newly introduced technique percutaneous pulmonary balloon angioplasty and/or P(A)H-targeted medical therapy has been shown to be beneficial in selected patients with CTEPH and might also be of importance in patients with chronic thromboembolic pulmonary vascular disease. Summary In this era of a comprehensive approach to CTEPH with different treatment modalities, a multidisciplinary approach guides management decisions leading to optimal treatment and follow-up of patients with CTEPH.
Source: Current Opinion in Cardiology - Category: Cardiology Tags: DISEASES OF THE AORTA, PULMONARY AND PERIPHERAL VESSELS: Edited by Alan Braverman Source Type: research

Related Links:

Conclusion: This is the first study describing the characteristics of CTEPH in the NPHU in Ireland. The annual incidence of 1.47 per million population would suggest that CTEPH may be underrecognised. Patients are typically older, there was no female predominance, and a history of prior PE was present in 65%, which is compatible with existing registry data.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pulmonary hypertension Source Type: research
In conclusion, the estimated survival of CTEPH patients at 1-, 3-, 5- and 7-year was 97.1%, 93.3%, 86.9%, and 82.0% respectively. The intervention of revascularization, including PEA and BPA, were preferred than treating with targeted drug alone in the view of long-term prognosis of CTEPH.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Singapore Med J. 2021 Jul;62(7):318-325. doi: 10.11622/smedj.2021089.ABSTRACTChronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary hypertension resulting from obstruction of the pulmonary artery by fibrotic thromboembolic material, usually initiated by recurrent or incomplete resolution of pulmonary embolism. This distinct form of pulmonary hypertension is classified under Group 4 of the World Health Organization classification. Further investigations are usually initiated, with transthoracic echocardiography followed by right heart catheterisation and pulmonary angiography as the gold standar...
Source: Singapore Medical Journal - Category: General Medicine Authors: Source Type: research
More News: Angioplasty | Baloon Angioplasty | Cardiology | Epidemiology | Heart | Hypertension | Pulmonary Hypertension | Pulmonary Thromboembolism | Study